The FDA has approved Triesence 40mg/mL (triamcinolone acetonide injectable suspension, from Alcon), a preservative-free synthetic corticosteroid for use in eye surgery and treatment of sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids.